Healthcare / BiotechnologyMexico
$63.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-18.8M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-61.1%
↓Gross Margin
N/A
•Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.4%
FCF CAGR
—
FCF margin
-334.5%
FCF / Net income
1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $40.4M · net income $-119.7M · FCF $-135.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.4M | $40.4M | $80.0M | $250.0M | $40.9M |
| Net Income | $-119.7M | $-119.7M | $-65.0M | $132.3M | $-46.4M |
| EBITDA | $-127.8M | $-127.8M | $-78.6M | $126.5M | $-44.6M |
| EPS | -2.04 | -2.04 | -1.13 | 2.97 | -1.21 |
| Operating Margin | -326.6% | -326.6% | -104.1% | 48.8% | -124.3% |
| Net Margin | -296.5% | -296.5% | -81.3% | 52.9% | -113.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.15 | 0.09 | 0.39 |
| Current Ratio | 8.42 | 8.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-135.1M | $-135.1M | $-18.8M | $74.7M | $-15.0M |
| Returns | |||||
| ROE | -61.1% | -61.1% | -21.7% | 56.0% | -78.6% |
| Valuation | |||||
| P/E | — | — | — | 49.83 | — |
| EV/EBITDA | — | — | — | 51.78 | — |
| P/B | 18.86 | 18.86 | 31.74 | 27.91 | 123.48 |
| Growth & Yield | |||||
| Revenue Growth | -49.5% | -49.5% | -68.0% | 511.2% | — |
| EPS Growth | -80.5% | -80.5% | -138.0% | 345.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.13 → -2.04
Residual
+6.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.